Genetic Testing to Select Targeted Therapies for Patients With Non-Small Cell Lung Cancer

Jyoti Patel, MD


March 05, 2020

A better understanding of the biology of non-small cell lung cancer has led to the discovery of driver mutations and therapies that target them. Next-generation sequencing, a type of genetic testing in which multiple genes can be screened with just one tissue sample, has become the preferred method of mutation testing in patients with advanced disease.

Dr Jyoti Patel of Northwestern University in Chicago, Illinois, discusses the benefits of genetic testing in patients with NSCLC, focusing on the identification of targeted therapies that outperform chemotherapy and single-agent immunotherapy in patients who have specific driver mutations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.